[1]
|
Zhang, X., Xiao, L., Zhang, L., et al. (2022) Associated Factors for Prostate Enlargement in Chinese Adult Men Aged <40 Receiving Checkups. International Journal of Clinical Practice, 2022, Article ID: 4792451.
https://doi.org/10.1155/2022/4792451
|
[2]
|
Egan, K.B. (2016) The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urologic Clinics of North America, 43, 289-297.
https://doi.org/10.1016/j.ucl.2016.04.001
|
[3]
|
Saito, M., Tsounapi, P., Oikawa, R., et al. (2014) Prostatic Ischemia Induces Ventral Prostatic Hyperplasia in the SHR; Possible Mechanism of Development of BPH. Scientific Reports, 4, Article No. 3822.
https://doi.org/10.1038/srep03822
|
[4]
|
Oelke, M., Gericke, A. and Michel, M.C. (2014) Cardiovascular and Ocular Safety of α1-Adrenoceptor Antagonists in the Treatment of Male Lower Urinary Tract Symptoms. Expert Opinion on Drug Safety, 13, 1187-1197.
https://doi.org/10.1517/14740338.2014.936376
|
[5]
|
Gul, A., Coban, S., Turkoglu, A.R., et al. (2020) Comparative Efficacy and Safety Profile of 4 vs 8 mg of Silodosin Once Daily Usage in Patients with Benign Prostatic Hyperplas-ia-Related Lower Urinary Tract Symptoms Divided into Subgroups According to International Prostate Symptom Score Severity. Prostate International, 8, 152-157.
https://doi.org/10.1016/j.prnil.2020.04.002
|
[6]
|
王志嵩, 李庆元. 非那雄胺治疗良性前列腺增生症临床分析[J]. 人人健康, 2019(24): 13.
|
[7]
|
段刘剑, 钱苏波. 前列腺增生患者应用非那雄胺治疗前后前列腺移行带体积变化的临床意义[J]. 现代泌尿外科杂志, 2021, 26(10): 831-835.
|
[8]
|
彭昊. 非那雄胺、坦索罗辛和特拉唑嗪治疗良性前列腺增生症的疗效比较[J]. 中国实用医药, 2017, 12(21): 111-113.
|
[9]
|
Nizov, A.N. (2019) Efficacy of 5-Reductase Inhibitors in the Treatment of Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia. Urologiia (Moscow, Russia: 1999), 5, 156-160.
https://doi.org/10.18565/urology.2019.5.156-160
|
[10]
|
Traish, A.M. (2020) Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’s Time to Sound the Alarm. World Journal of Men’s Health, 38, 323-337. https://doi.org/10.5534/wjmh.200012
|
[11]
|
Van Kerrebroeck, P., Kreder, K., Jonas, U., et al. (2001) Tolterodine Once-Daily: Superior Efficacy and Tolerability in the Treatment of the Overactive Bladder. Urology, 57, 414-421. https://doi.org/10.1016/S0090-4295(00)01113-4
|
[12]
|
Mónica, F.Z. and De Nucci, G. (2019) Tadalafil for the Treatment of Benign Prostatic Hyperplasia. Expert Opinion on Pharmacotherapy, 20, 929-937. https://doi.org/10.1080/14656566.2019.1589452
|
[13]
|
Ückert, S., Richter, K., Fischer, K.-D., Tsikas, D. and Kuczyk, M.A. (2021) Re-Evaluation of the Immunohistochemical Distribution of Isoforms of Nitric Oxide Synthase in the Human Prostate: A Light and Electron Microscopical Study. Andrologia, 53, e14098. https://doi.org/10.1080/14656566.2019.1589452
|
[14]
|
Shimizu, S., Nagao, Y., Kataoka, T., et al. (2020) Protective Effects of Tadalafil on Prostatic Hyperplasia in Spontaneously Hypertensive Rats. European Journal of Pharmacology, 882, Article ID: 173313.
https://doi.org/10.1016/j.ejphar.2020.173313
|
[15]
|
Yamaguchi, O. (2013) Latest Treatment for Lower Urinary Tract Dysfunction: Therapeutic Agents and Mechanism of Action. International Journal of Urology, 20, 28-39. https://doi.org/10.1111/iju.12008
|
[16]
|
Coelho, A., Antunes-Lopes, T., Gillespie, J. and Cruz, F. (2017) Beta-3 Ad-renergic Receptor Is Expressed in Acetylcholine-Containing Nerve Fibers of the Human Urinary Bladder: An Immuno-histochemical Study. Neurourology and Urodynamics, 36, 1972-1980. https://doi.org/10.1002/nau.23224
|
[17]
|
Keam, S.J. (2018) Vibegron: First Global Approval. Drugs, 78, 1835-1839.
https://doi.org/10.1007/s40265-018-1006-3
|
[18]
|
Gleicher, S., Sebesta, E.M., Reynolds, W.S., Reynolds, S. and Dmochowski, R. (2022) Vibegron for the Treatment of Overactive Bladder: A Comprehensive Update. Expert Opinion on Pharmacotherapy, 23, 1479-1484.
https://doi.org/10.1080/14656566.2022.2126311
|
[19]
|
Nickel, J.C., Gilling, P., Tammela, T.L., et al. (2011) Com-parison of Dutasteride and Finasteride for Treating Benign Prostatic Hyperplasia: The Enlarged Prostate International Comparator Study (EPICS). BJU international, 108, 388-394.
https://doi.org/10.1111/j.1464-410X.2011.10195.x
|
[20]
|
Fong, Y.K., Milani, S. and Djavan, B. (2005) Role of Phytotherapy in Men with Lower Urinary Tract Symptoms. Current Opinion in Urology, 15, 45-48. https://doi.org/10.1097/00042307-200501000-00011
|
[21]
|
Ye, Z., Huang, J., Zhou, L., et al. (2019) Efficacy and Safety of Serenoa repens Extract among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Random-ized, Double-Blind, Placebo-Controlled Trial. Urology, 129, 172-179. https://doi.org/10.1016/j.urology.2019.02.030
|
[22]
|
于文晓. 良性前列腺增生症中西医结合多学科诊疗指南(2022版) [J]. 中国男科学杂志, 2022, 36(2): 96-102.
|
[23]
|
孙自学, 宋春生, 邢俊平, 等. 良性前列腺增生中西医结合诊疗指南(试行版) [J]. 中华男科学杂志, 2017, 23(3): 280-285.
|
[24]
|
李东. 王琦教授治疗良性前列腺增生的经验[J]. 中华中医药杂志, 2011, 26(2): 286-288.
|
[25]
|
徐桂兴, 罗廖君, 银子涵, 等. 基于数据挖掘近10年针灸治疗良性前列腺增生症用穴规律研究[J]. 世界科学技术-中医药现代化, 2020, 22(4): 1330-1340.
|